SLU-PP-332: what it is, what the studies show and where it stands
SLU-PP-332 is a synthetic small molecule that switches on the estrogen-related receptors ERR alpha, beta and gamma. It is not a peptide.
At a glance
US Not approved
Canada Not authorized
Group Weight loss and metabolic
Sources 12
Checked 10 Oct 2026What is SLU-PP-332?
SLU-PP-332 is a synthetic small molecule that switches on the estrogen-related receptors ERR alpha, beta and gamma. It is not a peptide. It has been studied in cells and mice as a compound that copies some effects of exercise. [1]
Other names: (E)-4-hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide.
How it has been given to people: no human use on record.
Looking for doses? SLU-PP-332 dosage chart and vial math
Is SLU-PP-332 approved in the US and Canada?
United States: Not FDA approved. Drugs@FDA has no application for it and no clinical trial is registered. [9]
Canada: No product is in the Health Canada Drug Product Database. A product labelled SLU-PP-332 was among unauthorized products Health Canada seized. [11]
Both were checked on 10 Oct 2026 against the regulators' own product databases.
Which approved products contain SLU-PP-332?
No approved medicine containing SLU-PP-332 was found in the US or Canada. Anything sold under this name is not a regulated product, so there is no label to check a dose against.
What human studies of SLU-PP-332 exist?
The 9 findings listed here: 9 from animal or lab work.
In mice it increased oxidative muscle fibers and let the animals run longer. [1]
The endurance test gave mice 50 mg per kg by injection into the abdomen twice a day for 7 days. [1]
The same paper reports no overt toxicity in mice at that dose over 10 days. [1]
In obese mice it reduced obesity and improved insulin sensitivity. [2]
The lab that made it reports that it lacks oral bioavailability, and describes a different compound, SLU-PP-915, as the orally active one. [3]
In a mouse model of heart failure from pressure overload it improved ejection fraction and survival. [4]
In 21-month-old mice treated for 8 weeks it reversed age-related kidney changes such as albumin in the urine. [5]
The only human material found: muscle cells grown from biopsies of inactive women were treated in the dish. Nobody was given the compound. [6]
Anti-doping researchers have mapped its breakdown products so that use by athletes can be detected. [7]
What are the side effects of SLU-PP-332?
No side effect data from human studies was found for SLU-PP-332. That is a gap in the research, not a sign that it is safe.
How does SLU-PP-332 compare with others in its group?
These are the peptides filed under weight loss and metabolic. The last column says whether a randomized human trial is on record for each.
| Peptide | US | Canada | Half-life | Randomized human trial |
|---|---|---|---|---|
| Retatrutide | Not approved, in trials | Not authorized | About 6 days, from a 12-week phase 1b trial of once-weekly dosing in people with type 2 diabetes (72 enrolled). | Yes |
| Tirzepatide | Approved, prescription | Authorized, prescription | About 5 days. | Yes |
| Semaglutide | Approved, prescription | Authorized, prescription | About 1 week. | Yes |
| Cagrilintide | Not approved, in trials | Not authorized | 159 to 195 hours, about 6.6 to 8.1 days, measured in a phase 1b trial where it was given with semaglutide 2.4 mg. | Yes |
| AOD-9604 | Not approved | Not authorized | Not found | Yes |
| 5-Amino-1MQ | Not approved | Not authorized | Not found | No |
| SLU-PP-332 | Not approved | Not authorized | Not found | No |
| HGH Fragment 176-191 | Not approved | Not authorized | Not found | No |
What could not be found
These were searched for and did not turn up. They are listed so a missing number is not mistaken for a hidden one.
- Any study in people. PubMed returned 10 records for SLU-PP-332 and none is a clinical trial, and ClinicalTrials.gov has no registered study [8].
- A human dose, a human half-life, or human side effects. None exists in the sources found.
- No approved label anywhere, so no official contraindications, interaction list, missed-dose rule or storage instructions.
- The mouse dose in the obesity study [2]. Its full text could not be downloaded from PubMed Central, and the abstract gives no dose.
- Its standing with WADA. The compound is not named on the Prohibited List page; whether a general class covers it was not determined.
SLU-PP-332 questions
Is SLU-PP-332 approved in the US?
Not FDA approved. Drugs@FDA has no application for it and no clinical trial is registered.
Is SLU-PP-332 authorized in Canada?
No product is in the Health Canada Drug Product Database. A product labelled SLU-PP-332 was among unauthorized products Health Canada seized.
Has SLU-PP-332 been tested in a randomized human trial?
No randomized human trial was found. What exists is listed under the studies heading on this page.
Sources
Each one was opened on 10 Oct 2026 and matched to the line it supports.
- Billon C et al. Synthetic ERRalpha/beta/gamma Agonist Induces an ERRalpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol 2023. PubMed 36988910.
- Billon C et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther 2024. PubMed 37739806.
- Billon C et al. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. J Pharmacol Exp Ther 2026. PubMed 41421047.
- Xu W et al. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation 2024. PubMed 37961903.
- Wang XX et al. Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. Am J Pathol 2023. PubMed 37717940.
- Bonanni R et al. Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study. Front Physiol 2025. PubMed 40692696.
- Moller T et al. In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential. Rapid Commun Mass Spectrom 2026. PubMed 41588687.
- ClinicalTrials.gov searches for SLU-PP-332 and SLU-PP (0 studies) clinicaltrials.gov.
- Drugs@FDA via openFDA: search for SLU-PP-332 (no match) api.fda.gov.
- Health Canada Drug Product Database: ingredient searches for SLU and SLU-PP-332 (no match) health-products.canada.ca.
- Health Canada public advisory: Unauthorized health products sold online and seized at Rize Fitness may pose serious health risks (2025-12-24) recalls-rappels.canada.ca.
- FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (PDF, updated May 14, 2026) fda.gov.
Next
SLU-PP-332 dosageWeight loss and metabolicStatus in Canada
DosageFacts is an information site. It is not medical advice. Talk to a licensed professional before using any medication.